Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2013
At a glance
- Drugs Everolimus (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned end date changed from 1 Feb 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 14 Jan 2011 New trial record